The COVID-19 pandemic poses a threat to our antibiotic infrastructure, which is already compromised due to a lack of new therapies. That threat makes antimicrobial stewardship even more important.
Amid the spread of COVID-19, testing for SARS-COV-2, the virus that causes it, is at the forefront of the battle. Patients rely on test results to confirm if they’ve acquired the coronavirus, and public health entities around globe rely on the data to learn how and where the virus is spreading.
Patients at the greatest risk for secondary infections, particularly infections that are resistant to first-line antibiotics, include people who are already vulnerable due to other conditions and diseases—like COVID-19. Because of that, antimicrobial resistance poses a significant additional threat, especially as healthcare systems become overburdened.